Laura Balan Balan Acquires 3,500 Shares of Hikma Pharmaceuticals (LON:HIK) Stock

Key Points

• Laura Balan, an insider at Hikma Pharmaceuticals, acquired 3,500 shares of the company's stock at an average price of GBX 1,821, totaling £63,735.
• Hikma Pharmaceuticals' stock has a market capitalization of £5.09 billion and a current consensus rating of "Buy" from analysts with a target price averaging GBX 2,627.50.
• Recent analyst reports have seen target price decreases from major banks, including JPMorgan and Deutsche Bank, suggesting a more cautious outlook on the stock.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) insider Laura Balan Balan purchased 3,500 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The shares were acquired at an average price of GBX 1,821 per share, for a total transaction of £63,735.

Hikma Pharmaceuticals Price Performance

Hikma Pharmaceuticals stock traded up GBX 15 during midday trading on Monday, hitting GBX 1,836. 250,613 shares of the company's stock were exchanged, compared to its average volume of 1,011,032. Hikma Pharmaceuticals PLC has a 52-week low of GBX 1,690 and a 52-week high of GBX 2,360. The stock has a 50-day moving average price of GBX 1,942.31 and a two-hundred day moving average price of GBX 2,014.77. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The company has a market cap of £5.09 billion, a P/E ratio of 18.02, a PEG ratio of 2.38 and a beta of 0.41.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. JPMorgan Chase & Co. reduced their target price on Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an "overweight" rating for the company in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft cut their price objective on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a "buy" rating for the company in a report on Tuesday, August 12th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a GBX 2,600 price objective on shares of Hikma Pharmaceuticals in a report on Thursday, August 7th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of GBX 2,627.50.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.